Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study

Autor: Finkelstein J, Friedman C, Hripcsak G, Cabrera M

Publikováno v: Pharmacogenomics and Personalized Medicine, Vol Volume 9, Pp 107-116 (2016)

Joseph Finkelstein,1 Carol Friedman,1 George Hripcsak,1 Manuel Cabrera,2 1Department of Biomedical Informatics, 2Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract: Pharmacogenetic testing ident

Externí odkaz: https://doaj.org/article/babb5d0796a549ada4d465423d63c91c

750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC).

Autor: Friedman, C.¹ (AUTHOR), De Burgh Williams, A.² (AUTHOR), Lopez, J.S.³ (AUTHOR), Ouali, K.⁴ (AUTHOR), Middleton, M.R.⁵ (AUTHOR), Thistlethwaite, F.⁶ (AUTHOR), Hamid, O.⁷ (AUTHOR), Izar, B.⁸ (AUTHOR), Garcia, V. Moreno⁹ (AUTHOR), Johnson, M.L.¹⁰ (AUTHOR), Davar, D.¹¹ (AUTHOR), Martin-Liberal, J.¹² (AUTHOR), Roxburgh, P.¹³ (AUTHOR), Moore, K.N.¹⁴ (AUTHOR), Olson, D.¹⁵ (AUTHOR), Rottey, S.¹⁶ (AUTHOR), Kirk, P.B.¹⁷ (AUTHOR), Yuan, Y.¹⁸ (AUTHOR), Marshall, S.¹⁹ (AUTHOR), Yeku, O.²⁰ (AUTHOR)

Publikováno v: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS569-S570. 2p.

991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors

Autor: Sanborn, R.E., Patel, M.R., Rodon, J., Thein, K.Z., Friedman, C., Levitz, D., Ngirailemesang, I., Goodman, A., Agarwal, P., Friedman, E., Danaee, H., Robell, K., Jaeger, S., Sun, H., Debanne, E., Dunn, J., Wright, E., Reilly, T., Luke, J.J., Redig, A.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S675-S676

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.